X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (101493) 101493
Newsletter (1230) 1230
Book Chapter (470) 470
Magazine Article (457) 457
Newspaper Article (356) 356
Dissertation (313) 313
Publication (159) 159
Conference Proceeding (128) 128
Book / eBook (57) 57
Government Document (38) 38
Web Resource (28) 28
Reference (25) 25
Book Review (16) 16
Streaming Video (9) 9
Journal / eJournal (4) 4
Report (4) 4
Paper (3) 3
Transcript (3) 3
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (62317) 62317
heparin (38827) 38827
male (26177) 26177
female (26096) 26096
animals (23296) 23296
heparin - therapeutic use (16672) 16672
middle aged (15844) 15844
heparin - pharmacology (13991) 13991
adult (13813) 13813
aged (12580) 12580
anticoagulants - therapeutic use (11064) 11064
heparin - administration & dosage (9611) 9611
hematology (9428) 9428
anticoagulants (9259) 9259
molecular-weight heparin (8166) 8166
peripheral vascular disease (8080) 8080
biochemistry & molecular biology (7209) 7209
thrombosis (7128) 7128
heparin - adverse effects (6919) 6919
surgery (6555) 6555
rats (6442) 6442
cardiac & cardiovascular systems (5883) 5883
risk factors (5872) 5872
time factors (5827) 5827
anticoagulants - administration & dosage (5743) 5743
treatment outcome (5490) 5490
anticoagulants - adverse effects (5335) 5335
heparin - metabolism (5279) 5279
mice (5180) 5180
heparin, low-molecular-weight - therapeutic use (4977) 4977
pregnancy (4584) 4584
prevention (4519) 4519
medicine, general & internal (4510) 4510
venous thromboembolism (4427) 4427
glycosaminoglycans (4340) 4340
thromboembolism (4328) 4328
unfractionated heparin (4187) 4187
research (4040) 4040
pharmacology & pharmacy (3890) 3890
fibrinolytic agents - therapeutic use (3736) 3736
analysis (3539) 3539
deep-vein thrombosis (3537) 3537
aged, 80 and over (3480) 3480
binding (3459) 3459
dose-response relationship, drug (3413) 3413
kinetics (3397) 3397
prospective studies (3376) 3376
heparin - chemistry (3370) 3370
adolescent (3356) 3356
cells, cultured (3299) 3299
anticoagulation (3298) 3298
thrombocytopenia - chemically induced (3296) 3296
therapy (3216) 3216
protein binding (3186) 3186
blood coagulation - drug effects (3149) 3149
anticoagulants - pharmacology (3133) 3133
retrospective studies (3118) 3118
molecular sequence data (3070) 3070
proteins (2821) 2821
thrombin (2814) 2814
molecular weight (2805) 2805
cell biology (2782) 2782
risk (2769) 2769
enoxaparin (2703) 2703
expression (2701) 2701
postoperative complications - prevention & control (2684) 2684
rabbits (2668) 2668
venous thrombosis (2662) 2662
thromboembolism - prevention & control (2627) 2627
heparin-induced thrombocytopenia (2599) 2599
thrombosis - prevention & control (2582) 2582
blood (2559) 2559
amino acid sequence (2546) 2546
cattle (2530) 2530
care and treatment (2526) 2526
binding sites (2511) 2511
blood coagulation tests (2477) 2477
in vitro techniques (2437) 2437
health aspects (2402) 2402
activation (2393) 2393
cardiopulmonary bypass (2367) 2367
management (2351) 2351
cancer (2344) 2344
pulmonary embolism (2343) 2343
hemorrhage - chemically induced (2314) 2314
partial thromboplastin time (2311) 2311
warfarin (2309) 2309
heparin, low-molecular-weight - administration & dosage (2306) 2306
child (2252) 2252
coagulation (2249) 2249
prophylaxis (2239) 2239
drug therapy, combination (2223) 2223
diagnosis (2185) 2185
drug therapy (2165) 2165
low molecular weight heparin (2126) 2126
blood coagulation (2114) 2114
thrombolytic therapy (2111) 2111
abridged index medicus (2099) 2099
dogs (2073) 2073
aspirin (2060) 2060
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (40) 40
Online Resources - Online (23) 23
Gerstein Science - Theses (4) 4
University Archives - Archives (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Stacks (2) 2
Thomas Fisher Rare Book - Rare Book (2) 2
Collection Dvlpm't (Acquisitions) - Pharmacy (1) 1
Credit Valley Hospital - Closed Orders (1) 1
Gerstein Science - Pharmacy (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Online (1) 1
Toronto East General Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (90796) 90796
German (4407) 4407
French (3171) 3171
Russian (2209) 2209
Japanese (1629) 1629
Spanish (1090) 1090
Italian (1015) 1015
Polish (533) 533
Chinese (524) 524
Portuguese (361) 361
Czech (267) 267
Hungarian (163) 163
Dutch (129) 129
Korean (126) 126
Swedish (122) 122
Danish (100) 100
Turkish (100) 100
Romanian (87) 87
Norwegian (67) 67
Bulgarian (66) 66
Slovak (55) 55
Ukrainian (52) 52
Finnish (34) 34
Croatian (33) 33
Serbian (30) 30
Hebrew (24) 24
Slovenian (11) 11
Lithuanian (7) 7
Persian (7) 7
Afrikaans (6) 6
Breton (3) 3
Arabic (2) 2
Bosnian (2) 2
Icelandic (2) 2
Estonian (1) 1
Greek (1) 1
Latin (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation (New York, N.Y.), ISSN 1524-4539, 2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
no | Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 05/2008, Volume 99, Issue 5, pp. 807 - 818
Journal Article
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2018, Volume 2019, Issue 2, p. CD006649
Background Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to... 
'ORPHAN' TOPICS CURRENTLY BEING ADDRESSED | Anticoagulants | Recurrence | Tinzaparin | Secondary Prevention | Heparin, Low‐Molecular‐Weight | Fibrinolytic Agents | Hemorrhage | Neoplasms | Randomized Controlled Trials as Topic | Thrombophilia & other causes of thrombosis | Polysaccharides | Venous Thromboembolism | Dalteparin | Treatment of miscellaneous conditions in cancer | Fondaparinux | Heparin | Heart & circulation | Medicine General & Introductory Medical Sciences | Thrombo‐embolism prevention & treatment | General cancer treatments | Cancer | Fibrinolytic Agents [therapeutic use] | EXTERNAL PNEUMATIC COMPRESSION | RISK-FACTORS | STANDARD HEPARIN | Venous Thromboembolism [drug therapy; mortality] | Humans | RANDOMIZED CLINICAL-TRIAL | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | INTRAVENOUS UNFRACTIONATED HEPARIN | FACTOR-BEARING MICROPARTICLES | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | Polysaccharides [therapeutic use] | Dalteparin [therapeutic use] | LONG-TERM TINZAPARIN | Heparin [therapeutic use] | Heparin, Low-Molecular-Weight [therapeutic use] | Neoplasms [complications] | Anticoagulants [therapeutic use] | Polysaccharides - therapeutic use | Venous Thromboembolism - mortality | Anticoagulants - therapeutic use | Heparin - therapeutic use | Heparin, Low-Molecular-Weight - therapeutic use | Venous Thromboembolism - drug therapy | Neoplasms - complications | Dalteparin - therapeutic use | Fibrinolytic Agents - therapeutic use | Hemorrhage - chemically induced
Journal Article